- Previous Close
0.9285 - Open
0.9285 - Bid 0.8008 x --
- Ask 0.8808 x --
- Day's Range
0.9285 - 0.9285 - 52 Week Range
0.1402 - 1.2000 - Volume
200 - Avg. Volume
485 - Market Cap (intraday)
1.154B - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date Mar 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
www.ascletis.comRecent News: ASCLF
View MorePerformance Overview: ASCLF
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASCLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASCLF
View MoreValuation Measures
Market Cap
941.35M
Enterprise Value
674.54M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.81k
Price/Book (mrq)
4.24
Enterprise Value/Revenue
3.82k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-10.96%
Return on Equity (ttm)
-13.97%
Revenue (ttm)
1.28M
Net Income Avi to Common (ttm)
-300.94M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.95B
Total Debt/Equity (mrq)
0.39%
Levered Free Cash Flow (ttm)
--